Major Histocompatibility Complex– tag –
-
Technology Networks Delineates Commercialization Strategies for iPSC Therapies: Automated Manufacturing and Immune-Evasive Cell Line Development are Key
Technology Networks UK Overview Technology Networks provides an in-depth analysis of strategic challenges and solutions for the commercial viability of iPSC-based therapies, emphasizing the critical importance of scalable manufacturing, ... -
Commercial-Scale iPSC Cell Therapy: Advancements in Off-the-Shelf Treatments, Immunogenicity, and Cost Reduction are Key
The Medicine Maker UK Overview This article examines the challenges and technological advances in scaling induced pluripotent stem cell (iPSC) platforms for commercial cell therapies. It highlights the shift towards allogeneic, off-the-s... -
INFORMA Database Analysis Reveals Rapid Growth of Allogeneic NK Cell Immunotherapy, CAR-Engineered NK Cells Transitioning to Standardized Platforms
INFORMA database (journal article) International Overview Natural killer (NK) cell-based immunotherapy is gaining increasing prominence as a cancer treatment strategy due to its inherent cytotoxicity, allogeneic potential, and compatibil... -
Allogeneic CAR-T Manufacturing: Unlocking Rapid, Off-the-Shelf Cancer Therapy
Liv Hospital Turkey Overview Allogeneic CAR-T cell manufacturing is poised to revolutionize cancer treatment by providing 'off-the-shelf' solutions derived from healthy donor cells. This approach dramatically shortens treatment timelines... -
Gene-Edited iPSC-Derived CAR-T/NK Therapies Target Allogeneic Rejection for Off-the-Shelf Cancer Immunotherapy
MDPI Switzerland Overview Allogeneic T cell therapies represent a scalable, off-the-shelf alternative to autologous approaches, promising to overcome significant logistical and manufacturing limitations. The review highlights iPSC-derive... -
CAR-T Cell Therapy for Autoimmune Diseases Achieves 40-60% Cost Reduction and Sub-7-Day Manufacturing Through Gene Editing and Process Optimization
Market Intelo USA Overview Advances in gene-editing technologies are significantly reducing alloreactivity risk in allogeneic CAR-T products and cutting production costs by an estimated 40-60%. Next-generation allogeneic platforms aim to... -
Syntax Bio & Applied StemCell Partner to Accelerate Allogeneic iPSC Therapies with Low-Immunogenicity Lines and Cellgorithm Platform
Manufacturing Chemist USA Overview Syntax Bio and Applied StemCell have formed a strategic partnership to accelerate programmable iPSC therapy development. This collaboration aims to address key challenges of immune recognition and manuf... -
Preprint Reviews NKG2D CAR-NK Cell Progress in Cancer Immunotherapy: Low GVHD Risk, Scalable Manufacturing, and iPSC-Derived NK Cells as a Platform for Off-the-Shelf Therapies
Preprints.org International Overview A preprint on Preprints.org reviews recent progress in NKG2D CAR-NK cells for cancer immunotherapy, highlighting their favorable safety profile with rare instances of graft-versus-host disease (GVHD) ...
1